FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021231662> ?p ?o ?g. }

• W2021231662 endingPage "6532" @default.
• W2021231662 startingPage "6528" @default.
• W2021231662 abstract "Abstract Adult T-cell leukemia/lymphoma (ATL) is resistant to chemotherapy and carries a dismal prognosis particularly for the acute and lymphoma subtypes. Promising results were obtained with the combination of zidovudine and interferon-alpha. Chronic ATL has a relatively better outcome, but poor long-term survival is noted when patients are managed with a watchful-waiting policy or with chemotherapy. In ATL cell lines, arsenic trioxide shuts off constitutive NF-κB activation and potentiates interferon-alpha apoptotic effects through proteasomal degradation of Tax. Clinically, arsenic/interferon therapy exhibits some efficacy in refractory aggressive ATL patients. These results prompted us to investigate the efficacy and safety of the combination of arsenic, interferon-alpha, and zidovudine in 10 newly diagnosed chronic ATL patients. An impressive 100% response rate was observed including 7 complete remissions, 2 complete remissions but with more than 5% circulating atypical lymphocytes, and 1 partial response. Responses were rapid and no relapse was noted. Side effects were moderate and mostly hematologic. In conclusion, treatment of chronic ATL with arsenic, interferon-alpha, and zidovudine is feasible and exhibits an impressive response rate with moderate toxicity. Long-term follow up will clarify whether this will translate to disease cure. Overall, these clinical results strengthen the concept of oncogene-targeted cancer therapy." @default.
• W2021231662 created "2016-06-24" @default.
• W2021231662 creator A5032928140 @default.
• W2021231662 creator A5039260981 @default.
• W2021231662 creator A5042533344 @default.
• W2021231662 creator A5045802662 @default.
• W2021231662 creator A5049147739 @default.
• W2021231662 creator A5052878669 @default.
• W2021231662 creator A5057537682 @default.
• W2021231662 creator A5059441333 @default.
• W2021231662 creator A5069065596 @default.
• W2021231662 creator A5073244224 @default.
• W2021231662 creator A5084597724 @default.
• W2021231662 creator A5087343974 @default.
• W2021231662 creator A5088509972 @default.
• W2021231662 creator A5088794779 @default.
• W2021231662 creator A5089460101 @default.
• W2021231662 creator A5089885174 @default.
• W2021231662 date "2009-06-25" @default.
• W2021231662 modified "2023-09-30" @default.
• W2021231662 title "Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)" @default.
• W2021231662 cites W1586205537 @default.
• W2021231662 cites W1606216715 @default.
• W2021231662 cites W1980124550 @default.
• W2021231662 cites W1986265440 @default.
• W2021231662 cites W1995670792 @default.
• W2021231662 cites W2009621572 @default.
• W2021231662 cites W2029439010 @default.
• W2021231662 cites W2051523398 @default.
• W2021231662 cites W2055182902 @default.
• W2021231662 cites W2062772646 @default.
• W2021231662 cites W2063083122 @default.
• W2021231662 cites W2065141696 @default.
• W2021231662 cites W2085882015 @default.
• W2021231662 cites W2123087041 @default.
• W2021231662 cites W2134594325 @default.
• W2021231662 cites W2158377087 @default.
• W2021231662 cites W2162622294 @default.
• W2021231662 cites W2271053812 @default.
• W2021231662 cites W2323754647 @default.
• W2021231662 cites W4230033805 @default.
• W2021231662 doi "https://doi.org/10.1182/blood-2009-03-211821" @default.
• W2021231662 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19411628" @default.
• W2021231662 hasPublicationYear "2009" @default.
• W2021231662 type Work @default.
• W2021231662 sameAs 2021231662 @default.
• W2021231662 citedByCount "167" @default.
• W2021231662 countsByYear W20212316622012 @default.
• W2021231662 countsByYear W20212316622013 @default.
• W2021231662 countsByYear W20212316622014 @default.
• W2021231662 countsByYear W20212316622015 @default.
• W2021231662 countsByYear W20212316622016 @default.
• W2021231662 countsByYear W20212316622017 @default.
• W2021231662 countsByYear W20212316622018 @default.
• W2021231662 countsByYear W20212316622019 @default.
• W2021231662 countsByYear W20212316622020 @default.
• W2021231662 countsByYear W20212316622021 @default.
• W2021231662 countsByYear W20212316622022 @default.
• W2021231662 countsByYear W20212316622023 @default.
• W2021231662 crossrefType "journal-article" @default.
• W2021231662 hasAuthorship W2021231662A5032928140 @default.
• W2021231662 hasAuthorship W2021231662A5039260981 @default.
• W2021231662 hasAuthorship W2021231662A5042533344 @default.
• W2021231662 hasAuthorship W2021231662A5045802662 @default.
• W2021231662 hasAuthorship W2021231662A5049147739 @default.
• W2021231662 hasAuthorship W2021231662A5052878669 @default.
• W2021231662 hasAuthorship W2021231662A5057537682 @default.
• W2021231662 hasAuthorship W2021231662A5059441333 @default.
• W2021231662 hasAuthorship W2021231662A5069065596 @default.
• W2021231662 hasAuthorship W2021231662A5073244224 @default.
• W2021231662 hasAuthorship W2021231662A5084597724 @default.
• W2021231662 hasAuthorship W2021231662A5087343974 @default.
• W2021231662 hasAuthorship W2021231662A5088509972 @default.
• W2021231662 hasAuthorship W2021231662A5088794779 @default.
• W2021231662 hasAuthorship W2021231662A5089460101 @default.
• W2021231662 hasAuthorship W2021231662A5089885174 @default.
• W2021231662 hasBestOaLocation W20212316621 @default.
• W2021231662 hasConcept C126322002 @default.
• W2021231662 hasConcept C143998085 @default.
• W2021231662 hasConcept C190283241 @default.
• W2021231662 hasConcept C203014093 @default.
• W2021231662 hasConcept C2776178377 @default.
• W2021231662 hasConcept C2776694085 @default.
• W2021231662 hasConcept C2778461978 @default.
• W2021231662 hasConcept C2780216070 @default.
• W2021231662 hasConcept C2780386689 @default.
• W2021231662 hasConcept C2780727368 @default.
• W2021231662 hasConcept C2781228144 @default.
• W2021231662 hasConcept C2909179924 @default.
• W2021231662 hasConcept C3013748606 @default.
• W2021231662 hasConcept C55493867 @default.
• W2021231662 hasConcept C71924100 @default.
• W2021231662 hasConcept C86803240 @default.
• W2021231662 hasConcept C90924648 @default.
• W2021231662 hasConceptScore W2021231662C126322002 @default.
• W2021231662 hasConceptScore W2021231662C143998085 @default.
• W2021231662 hasConceptScore W2021231662C190283241 @default.
• W2021231662 hasConceptScore W2021231662C203014093 @default.

• next